Drug Insights

Strategically Search Mupirocin on Synapse: A How-to Guide

22 February 2024
2 min read

Mupirocin, also known as BACTROBAN, is an antibacterial medication that inhibits RNA synthetase and is used topically to treat impetigo caused by Staphylococcus aureus and Streptococcus pyogenes. It was first approved by the FDA in 1987 and is produced by GlaxoSmithKline. Impetigo is a contagious skin infection that causes blisters and crusts, commonly seen in children. BACTROBAN comes in cream, ointment, or nasal form and is applied directly to the affected area. It is generally well-tolerated, but some people may experience allergic reactions. BACTROBAN is an important tool in managing impetigo as it helps control the spread of infection and promotes healing. Click on the image below to begin the exploration journey of Mupirocin through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

FDA Approves Kurome's Clinical Trials for AML and Advanced MDS Drug KME-0584
Latest Hotspot
3 min read
FDA Approves Kurome's Clinical Trials for AML and Advanced MDS Drug KME-0584
22 February 2024
Kurome Therapeutics has received authorization from the FDA to conduct clinical trials for KME-0584, aimed at addressing Acute Myeloid Leukemia (AML) and advanced-stage Myelodysplastic Syndromes (MDS).
Read →
User-friendly Guide to Find Quetiapine on Synapse
Drug Insights
2 min read
User-friendly Guide to Find Quetiapine on Synapse
22 February 2024
Quetiapine, marketed as SEROQUEL, is an atypical antipsychotic medication developed and produced by AstraZeneca.
Read →
Acousia Therapeutics Begins Enrollment for Phase II of PROHEAR Trial
Latest Hotspot
3 min read
Acousia Therapeutics Begins Enrollment for Phase II of PROHEAR Trial
22 February 2024
Acousia Therapeutics disclosed that it has initiated participant enrollment for its second stage PROHEAR trial.
Read →
Harnessing Synapse for Methotrexate Information: Strategies and Tips
Drug Insights
2 min read
Harnessing Synapse for Methotrexate Information: Strategies and Tips
22 February 2024
Methotrexate, a DHFR-inhibiting drug approved in the US since 1953, is known for treating various conditions such as acute lymphoblastic leukemia, breast cancer, severe psoriasis, and rheumatoid arthritis in both adults and children.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.